Skip to main content

Eli Lilly Loses Some Luster

Eli Lilly's shares are getting hit by the combined pressure from an analyst downgrade and disappointing clinical trial results for a new cancer drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.